Avelas Biosciences to Present at JMP Securities Annual Life Sciences Conference
June 14, 2018
SAN DIEGO, June 14, 2018 – Avelas Biosciences, Inc., a clinical stage oncology-focused platform technology company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced that Carmine N. Stengone, President and Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Thursday, June 21, 2018, at 1:30 p.m. EDT (10:30 a.m. PDT) in New York City.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention. The company’s lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing. In addition, the company is advancing a therapeutic program, which utilizes the same technology platform. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.